Drug Approval | December 17, 2023
Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Recommendation is based on pivotal data from the phase III POLARIX study
First launches expected in H1 2022
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)